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0.1 – Abstract 
Human Immunodeficiency Virus (HIV) is a deadly and incurable illness impacting millions 
annually. Targeting the T-helper CD4+ cells of the immune system, HIV is a complex enveloped 
pseudo-diploid RNA virus. Of the nineteen proteins encoded, one of the most readily produced 
and unique is the p24 inner capsid protein. Current research suggests that gut-associated 
lymphoid tissue (GALT) may be one of the primary HIV reservoirs in the body. Due to the 
immense difficulty associated with a cure for the disease, a preventative vaccine remains the best 
possible defense. Orthoreovirus, a virus causing mild to no pathological conditions, is known to 
target the GI system. Recent advances in the field of Orthoreovirus reverse genetics allow for the 
possibility of this virus to be used in the creation of an HIV vaccine. We provide support that 
based on the segmented nature of the Orthoreovirus genome, 5’ duplication of the segments ORF 
is the best possibility for insertion of the p24 coding sequence for use as a vaccine antigen. We 
show there exists a maximum practical length for the length of code which can be added via the 
5’ duplication method, over which, recombination to original wild type occurs. This limit is an 
important consideration for future work and design with the Orthoreovirus.  
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1.0 - Introduction 
1.1 – Human Immunodeficiency Virus  
Human Immunodeficiency Virus, otherwise known as HIV, is the virus responsible for Acquired 
Immunodeficiency Syndrome, or AIDS1. The cause of millions of deaths each year2, AIDS is a 
potent and deadly disease that currently has no known preventative treatment or cure. HIV is a 
single stranded positive-sense pseudo-diploid RNA virus3, placing it within Class VI of the 
Baltimore Classification System. Due to the enveloped structure and long incubation periods, it 
is further classified within Class VI in the Retrovirus family and Lentivirus genus.  
There are currently two known species of HIV, classified as HIV-1 and HIV-24. The virus is 
believed to be the result of at least 11 zoonotic infections, arising from the transfer of simian 
immunodeficiency virus (SIV) in chimpanzees to humans5. A study of genomic markers places 
the first SIV infection in chimpanzees sometime around the year 1492 and the migration to 
humans by 19636. While HIV-2 is highly genetically similar to SIV, HIV-1 is both more virulent 
as well as more readily transferred. HIV-1 is classified into three groups, namely group M 
(main), O (other), and N (non-M/non-O), varying in slight genetic modifications, mainly in the 
capsid proteins. This variation is believed to have been, and continues to be, the result of viral 
escape mechanisms7. Group M is further broken down into 9 subgroups, again with slight 
variations. Further groups continue to arise as the result of genetic combination of two or more 
varying strains. 
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1.1.1 – Genome and Structure 
Several 
examples of 
complete 
HIV-1 
genomes 
have been sequenced, typically around 9700bp in length (Fig. 1) 8. The length varies slightly 
between strains due to mutations encountered during replication. Contained within the genome 
across three various reading frames are nine genes encoding for a total of nineteen proteins. Each 
gene codes for at least one protein, some coding for up to four, related in function, form or 
location. The genes referred to as group specific antigen, polymerase, envelope, transactivators, 
and regulators.  
Group specific antigen (gag) is a single gene responsible for the coding of four proteins, p6, p7, 
p17, and p24, all related to internal structural or core functions to the virus. Both p6 and p7 are 
nucleocapsids used to protect the RNA from degradation by way of nucleases, structured in a 
ratio of one molecule RNA per hexemer of protein9. p17 and p24 are both structural proteins, 
p24 being the main component of the inner capsid, and p17 used as the anchor to attach the inner 
capsid to the outer envelope as well as the proteins found therein.  
Polymerase (pol) gene encodes three main proteins responsible for the reverse transcriptase, 
protease, and integrases enzymes. Reverse transcriptase is the enzyme by which RNA is 
transcribed into DNA. In the case of Retrovirus, this is used in order to produce the material to 
insert the viral RNA genome into the host cell DNA genome. The enzyme that performs this task 
Figure: 1 – HIV HXB2 Genome. Depiction of genome, displaying three separate reading frames.  
Frame 1 containing gag, encoding for p17 and p14. Frame 3 containing tat. Frame 3 containing pol and 
env. Source: Los Alamos National Laboratory. 
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is integrase. Protease is the enzyme responsible for the cleavage of the fusion protein at specific 
predetermined locations. Without the cleavage performed by protease, the proteins are never 
separated, thus creating an inactive virion. 
Envelope (env) encodes for the exterior viral proteins. Making use of a host cell enzyme Furin, 
the fusion protein gp160 coded for my env, is cleaved into two smaller subunits, gp120 and 
gp4110. gp41 and gp120 present on the surface of the matured virion in the form of a 3:3 
complex. A gp41 trimer is directly attached to the exterior of the virion with the trimer gp120 
affixed onto the end of it. The role of gp41 is that of mechanical cellular entry into CD4+ cells11, 
as recognized by the gp120 complex12.  
The purpose of a transactivator is to selectively increase or decrease the rate of gene expression. 
The three produced by HIV are transactivator of transcription (tat), regulator of virion (rev), and 
viral protein-r (vpr). Tat works by enhancing the phosphorylation of cellular factors, thereby 
increasing their expression13. This allows for an explosive increase in copy count, proving 
difficult for the body to overcome. Rev is believed to assist with the exportation of RNA from the 
cell nucleus to the ctytoplasm, allowing for the increased production of RNA. Contrary to rev, 
vpr may potentially work by accelerating the import of viral precursor into the nucleus, to aid in 
RNA production.  
Three other miscellaneous regulatory factors are also present within HIV, viral infectivity factor 
(vif), negative regulatory factor (nef), and viral protein-u (vpu). Vif works to interrupt a main 
human antiviral protein, APOBEC, by targeting it for degradation by the bodies own immune 
system. Nef decreases the expression of MHC surface protein signals of the host cell, making it 
less likely to be marked for degradation by the immune system, and thereby increasing the 
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chances of virion survival. Vpu is involved in one of the final step of virion production, the 
budding of the virion from the host cell. 
The mature HIV virion is spherical in 
shape14 and roughly 120nm in diameter 
(Fig. 2)15. It contains both an outer and 
inner membrane. The inner membrane, 
conical in shape, is coded for by the gag 
protein p24 and contains the bulk of the 
encoded viral material, including RNA, 
reverse transcriptase, protease, and other 
accessory proteins. The RNA, in its mature packaged form, is tightly bound to p6 and p7 
proteins16. Immediately surrounding the p24 capsid is a membrane of p17 proteins, which are 
used to help anchor the outer membrane and its respective proteins to the inner capsid. The viral 
envelope, gained as a result of the virion buding off from the host cell, is largely composed of 
host cell material. Inserted into the outer envelope is a series of gp120/gp41 complexes, used to 
bind to CD4 as well as gain entry into the cell.  
1.1.2 – Lifecycle 
HIV primarily infects T-cells and macrophages of the human immune system (Fig. 3)17. The 
process is initiated by the infection of a human with a mature HIV virion. Once a mature virion 
has been transferred, it must come into contact with a T-helper cell. The gp120 protein located 
on the surface of the virion has a high affinity for the CD4 antigen present on the surface of the 
target cells, allowing for a strong bond to be formed. This bond is then further stabilized by 
Figure 2 - HIV Virion Structure. Representation of HIV 
structure. Gp120/gp41 complex on exterior, p17 matrix 
protein, p24 capsid protein, and RNS bound with necessary 
regulatory factors. Source: San Diego State University 
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recruited chemokine receptors on the surface of 
the host cell, most often CCR5. Once these 
accessory proteins are moved into the vicinity 
of both the CD4 and the gp120/gp41 complex, 
the bond strength and affinity are increased, 
causing a conformational change of the gp120 
to takes place. This change forces the gp41 
protein into the membrane of the host causing a 
fusion of the two membranes, allowing for 
inner capsid of the virion to be released into the 
cytoplasm of the host cell. 
Due to the fact that the HIV genome is 
composed of RNA and must be inserted into the 
DNA host cell genome, once the viral material has entered the host cell, the first step of virion 
production is reverse transcription. This process, performed by reverse transcriptase, is highly 
error prone due to the lack of correction as a result of the single stranded nature of the HIV 
genome. This leads to numerous and frequent mutations within the HIV genome. These 
mutations, while often times detrimental to the survival of the virus, can at lead to viral escape. 
Mutations, typically in protein structure, grant a lack of recognition to existing enzymes and 
pathways designed to recognize and act on the previous protein structure. These select mutations 
are further amplified and expanded by ways of natural selection; those which are most fit to 
survive will by probability, be the most likely to survive. 
Figure: 2 - HIV Lifecycle. Figure depicting the 
lifecycle and replication method of HIV. HIV 
attachment by mediation of CD4 receptor on T-
helper cells, followed by gencome integration, 
replication, and export of virion. Source: Molmo. 
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The virus itself lacks many of the pathways and enzymes necessary for replication. As such, 
once transcription from RNA to DNA takes place, the DNA copy of the viral genome must be 
inserted into the host cells DNA genome for use of the host cells natural pathways. Integrase 
facilities this action. Although integration of the genome allows for the possibility of virion 
production, it does not necessarily indicate it. Several transcription factors, one of the most vital 
being NF-κB, must be present for replication to occur. The majority of these factors are present 
only during activation of the host cell in an immune response. This is one of the major leading 
causes of the varying and prolonged HIV latency periods. Because T-cells can be latent memory 
cells for long periods of time, the virus genome can remain stored within the cells, dormant, until 
the cells become activated due to an immune response, initiating the actions of both the host and 
the viral genome. 
Once replication does occur, the initial resulting mRNA is cleaved within the cell nucleus and 
exported to the cytoplasm, where it is translated into tat and rev. Once the buildup of these 
proteins is sufficient, they being to bind to the mRNA particles within the nucleus prior to 
cleavage. These full-length particles are then exported from the nucleus where they are then used 
to translate the gag and env proteins used to build the virion itself. The buildup of tat and rev 
proteins continues in a positive feedback look until the maximum production rate of virion is 
achieved. 
The final step of virion production is egression, where it will obtain its viral envelope as well as 
surface proteins. The process begins as gp160 is produced and cleaved by protease into gp41 and 
gp120, which are moved to, and subsequently anchored to, the membrane of the infected cell. 
The adhesion of gp120 and gp41 cause a complex with the viral genome and associated factors 
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and proteins, including p24, to form. The formation of this complex causes endocytosis and 
formation of the virion.  
1.1.3 – Viral Transfer and Infection 
HIV is known to be transmitted horizontally by the transfer of blood, semen, vaginal fluid, and 
breast milk18. Infection can also occur vertically, to a child during pregnancy by an HIV positive 
mother. This risk can be reduced with precautionary measures, most often times the use of 
antiviral drugs19. HIV is not known to be transmitted via airborne methods or by saliva, making 
unprotected intercourse the primary means of proliferation. Due to lack of awareness and testing, 
in the 80’s and early 90’s, blood transfer from HIV positive donors to HIV negative patients was 
another major cause of proliferation20. However, due to advancements in testing, primarily the 
presence of testing, and population HIV awareness, this risk has been sufficiently eliminated.  
Emerging research suggests that CD4+ cells located in the gut-associated lymphoid tissue 
(GALT) may be a major reservoir of HIV in infected individuals21-22. This reservoir is present 
despite treatment of the individual to reduce blood pathogen level to undetectable amounts, 
suggesting that current methods of treatments may not be sufficient for the completion 
eradication of the virus. Levels of CD4+ cell were observed to be approximately 11% in GALT, 
while normally 40% in HIV positive patients, and 60% in healthy patients. Exchanges between 
this reservoir and the blood system have been observed, giving a possible cause to latency and 
prolonged infection periods.  
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1.2 – Orthoreovirus 
Reoviridae is a family of non-enveloped double stranded RNA virus in Class III of the Baltimore 
Classification System. Within the family is a distinction between turreted and nonturreted, with 
Orthoreovirus being the only genus within the family to infect humans. 
The Orthoreovirus genome is separated into a series of ten segments, placed into one of three 
size dependent groups, equimolar in quantity23. Each group encodes for a set of proteins, with 
small (S) encoding σ proteins, medium (M) encoding µ proteins, and long [L] encoding λ 
proteins. Segments are transcribed into full length mRNA strands for use in replication within 
the host cell and can undergo reassortment between virion and strands. The 5’-end of the genome 
is features a methylated nucleotide cap, important to the replication and proliferation of the virus. 
3’ ends also lacks polyadenylation. Replication takes place fully in the cytoplasm, indicating that 
the host cells replication enzymes are not necessary for viral replication. 
Spherical in shape, virions are approximately 80nm in diameter, and contain both an inner and 
outer capsid. The inner capsid is composed of four structural proteins (λ1, λ3, µ2, and σ2) and is 
approximately 60nm is diameter. The outer capsid, also encoded for by 4 structural proteins (λ2, 
µ1, σ1, and σ3), is icosahedral in shape with a triangulation number of 13.  
Orthoreovirus is the only geneses of Reovirus known to affect humans, causing gastrointestinal 
and upper respiratory tract infections in infant and young children24, ranging from mild to 
asymptomatic25. This feature, as well as the common location of infection Orthoreovirus shares 
with HIV, allow for a wide range of possibilities in the use of a vaccine vector. 
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1.3 – Immunology and Vaccine Construction 
Due to the deadly and debilitating nature of HIV and the lack of any known cure, the need arises 
for a vaccine to create a preventative measure. A vaccine is a step taken to prime the immune 
system, making it aware of a particular foreign substance. By increasing awareness for a 
particular toxin, the response time is reduced, and the toxin is eliminated before it is able to 
replicate and cause damage to the host.  
1.3.1 – Immune Responses 
Mammalian immune systems are composed of two parts, the innate and the adaptive system. The 
innate system is the omnipresent and continuously active network of precautions put in place by 
the body. These barriers include those created by cell walls and organs such as the skin, as well 
as basic responses such as inflammation. These responses do not have memory of previous 
toxins and cannot adapt in any way to newly presented toxins. The adaptive system, in contrast, 
does have the ability to learn and adjust to varying toxins, and is the main focus of vaccine 
delivery. 
One of the main functional unit of the adaptive system is the antigen26.  An antigen is a marker, 
typically the result of an enzyme digestion of a larger particle, that present on the surface of cells 
or as a free complex in tissue, to indicate self from non-self. Antigens present by way of a self-
enzyme, the Major histocompatability complex (MHC), a multi-subunit integral protein located 
on the cellular membrane. This complex, upon recognition of a non-self or incorrect self antigen, 
signals T-cells to destroy the antigen by way of degradation. The MHC complex is distinguished 
into two classes: Class I that is typically used in response to an endogenous antigen produced 
interior to the cell, and Class II that is typically in response to an exogenous antigen located 
exterior to the cell. Class I cells signal CD8+ cytotoxic T-cells while Class II signal CD4+ T-
Design of Recombinant HIV Vaccine by Orthoreovirus 5’ Duplication 
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helper cells. T-helper cells are unique within the immune system in that they do not posses any 
ability to dispose of a toxin without the use of other immune cells; because of this, an MHC 
Class II response is generally considered weaker and less effective then a Class I response as it 
must yet propagate a further immune response. Cells which are CD8+ and CD4- are largely 
unaffected by HIV, and therefore, are targets of use in the fight against HIV. 
1.3.2 – Vaccine Forms 
Depending on the virulent in question, the chemical composition, structural form, the method by 
which it enters and replicates, as well as several other mitigating factors, one vaccine form may 
be chosen over another. The most commonly used methods include attenuated, inactive, subunit, 
and recombinant viral vaccines27. 
Attenuated vaccines are those that use a live but altered form of the organism. The alterations are 
selected or performed in such a way as to disable any infectious or pathogenic properties. This 
allows for the body to mount a response closest to that of an actual infection, producing the 
strongest and most reliable defense. Because this form of vaccine relies on live particles, there 
are certain risk involved. It is possible in select cases for the virulent to revert back to infectious 
form, causing the disease that it was intended to prevent. The vaccine must also be stored and 
produced in such a way as to insure the virions contained within remain alive. The death of the 
virions could potentially lead to a lack of immune response from the host, causing a lack of 
immunity. 
Inactive vaccines use a once live organism that has been killed to the point of being unable to 
infect or reproduce. Even though the virulent cannot infect and reproduce, they are still identified 
as non-self and an immune response is mounted. As the case with attenuated, this form of 
Cameron W. Habib  15 
vaccine carries risks with it. If the virulent is not properly killed to a great enough extent, it is 
possible for the virulent to cause the disease instead of producing immunity to it.  
Subunit vaccines are those which use a small part of the whole virulent in order to create an 
immune response. Because some virulent produce proteins unique to that virulent, it is possible 
to create an immunity to the virulent as whole by creating an immunity to a unique part of it. 
Doing so avoids the use of the virulent in its full virion form, which in turns reduces the number 
of risks, such as infection and disease. The subunit can also be chosen, to select for specific 
properties or functions. However, because an immunity is only being created to a specific part of 
a whole, that specific part must be present for the response to take place. This in turn creates an 
immunity less robust and reliable. There are also a large number of proteins which cannot 
survive transportation into the body, either by injection or through the gastroenterological 
system, making the discovery and selection of such a protein difficult. 
Recombinant viral vaccine utilizes technologies from several different forms of vaccines, 
including attenuated and subunit vaccines. In a typical recombinant viral vaccine, a normally 
non-pathogenic virus, or one that has been altered to become such, is inserted with genetic code 
to produce a specific part of a virulent for which immunity is to be gained from. The host is 
infected with the recombinant virus which in turn produces the virulent protein, initiating an 
immune response, causing an immunity. Because the protein is produced in vivo and not in vitro, 
the protein does not have to be as robust or posses the ability to survive the transportation into 
the body. A recombinant virus can also be selected to cause an immune response or infection in a 
particular region of the host, allowing for selectivity in not only protein produced, but the 
location in which it is produced. 
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1.3.3 – HIV Vaccine 
Due to their ease of creation and effectiveness, two of the most commonly used forms of vaccine 
include attenuated and inactivated. However, because HIV’s viral envelope is, in essence, host 
material, producing a vaccine against this would cause an autoimmune response, whereby the 
body initiates an autoimmune response. Combined with the extremely virulent and robust nature 
of HIV, and the danger that the virus poses, the risks of creating an attenuated or inactivated 
vaccine for this virus are too high to be considered possible choices.  
HIV does present two unique proteins on the surface of its viral envelope, in specific gp120 and 
gp41, making subunit vaccine a possibility. These proteins, however, provide a poor target for 
vaccine production28. Because both gp120 and gp41 are glycoprotein, the majority of their 
structures lack the rigid and defined structural characteristics necessary to produce an effective 
antibody against them. The parts that do contain the necessary structural integrity, on a mature 
virion, are highly restricted, disallowing to a great degree any possibility of detection and 
response by the immune system. Because of this, an internal protein must be selected for vaccine 
investigation. 
One of the most readily produced and consistent proteins of HIV is the p24 protein encoded by 
gag. This protein has long been the target of HIV infection tests29, due in part to the proteins 
early production and numerous count. p24 is an also a protein exclusive to HIV and absent from 
uninfected individuals; creating an immunity to this will not cause an autoimmunity condition in 
any way. Because this protein does not code for any viral properties of the virus, and because it 
is not currently known to cause any pathology when separated from the viral particle, few if any 
side reactions will occur by use of this protein in vaccine. An analogue of the HIV p24 protein 
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also exists in the form of the SIV p24 protein. The existence of an analogue aids in vaccine 
construction and testing.  
Due to the harsh conditions of the digestive system, and the lack of ability for uptake of a protein 
in a fashion that would invoke an immunological response, a pill form containing such a protein 
would not be feasible. Injection into the blood stream would, likewise, mount a weak 
immunological response, leading to minor resistance to subsequent infection. Because of this, the 
protein must be produced in vivo. Production in vivo would allow for the highest possible 
chances of an MHC Class I response, allowing a much stronger viral infection resistance. The 
primary means for such a production is by recombinant viral vaccine. Such a vector would infect 
the host and produce the specified antigen, allowing the body to gain immunity to it. 
As previously discussed, HIV is thought to resonate within GALT. As such, a vector that targets 
GALT, rather then an alternate tissue, would prove to be the most effect vector. Orthoreovirus is 
one such possible viral vector that is known to mainly localize to the gut region. This, combined 
with its relatively low pathogenic characteristics, makes it a possible candidate for vaccine use. 
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2 – Materials and Methods 
2.1 – S3 Plasmid Construction 
An S3 plasmid stock from Type 3 (Dearing) strain of mammalian Ortheovirus was obtained 
(courtesy of Takeshi Kobayashi). A SIV p24 protein coding sequence was also obtained via 
consortium resources. 
2.1.1 – PCR 
PCR method for design of construct was established using three part PCR (Table 1). First PCR, 
designated [L], had primer sequences (L1) annealing at location 3074, and (L2) annealing at 
location 678. Second PCR, designated [R], had primer sequences (R1) annealing at location 
3052, and (R2) annealing at location 469. PCR [L] to amplify OOR, and initial 200bp of T3D 
ORF for duplication. PCR [R] to amplify the addition of 2A motif and ORF in entirety. Third 
PCR, designated [C], had primer sequence (C1) annealing to initial 5’ end p24, and (C2) to 
amplify region of SIV-p24 initial 5’ end 2A for inclusion into PCR [R]. PCR performed in 25µL, 
using PFU Turbo (Stratagen cat. #600250) and associated buffer according to manufactures 
protocols. Products run on 1% agarose gel with Invitrogen TrackIt 1KB DNA ladder in 1x TBE. 
2.1.2 – Ligation 
0.5µL DpnI and associated buffer added to 20 µL PCR [R] and [L] and allowed sit for 1 hour at 
37°C for elimination of methylated parent strand. PCR product purified using PureLink PCR 
Purification Kit (Invitrogen cat. #K3100-01) according to manufactures protocols. PNK with 
associated buffer added and allowed sit 1 hour at 37°C for 5’ phosphate addition due to lack on 
primer design. 2 µL T4 DNA Ligase and associated buffer added and let sit overnight at 16°C for 
ligation of PCR products. 
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2.2 – Bacterial Transfection 
Previously prepared competent DH5α cell stock in DMSO obtained. 10µL ligated product mixed 
with 200µL cell aliquot. Allowed incubate 1 hour on ice. Heat shocked 1.5 minute at 42°C. Cells 
plated to Amp+ plate. Allowed incubate overnight at 37°C. Individual colony selected, 
transferred to 3mL LB media. Allowed incubate overnight at 37°C. 3mL incubation transferred 
spun down and plasmid purified using PureLink Quick Plasmid Miniprep Kit (Invitrogen cat. 
#K2100-11) according to manufactures protocols. Plasmid sent for sequencing. Plasmid added to 
200 µL aliquot of competent DH5α cells. Allowed incubate 1 hour on ice. Heat shocked 1.5 
minute at 47°C. Added to 100mL LB media for growth. Allowed incubate overnight at 37°C.  
100mL LB media incubation growth spun down. Aliquot purified using Endofree Plasmid Maxi 
Kit (Qiagen cat. #12362) according to manufactures protocols. Plasmid resuspended 500µL TE. 
2.3 – Reovirus Reverse Genetics 
Method for the reverse genetic engineering of reovirus is adapted from that of Takeshi 
Kobayashi30. 
2.3.1 – Infection with Vaccinia Virus 
Sonicated Vaccinia Virus (VV) rDIs-T7pol by cup sonication. L cells infected with 0.5-1mL 
Opti-MEM I (Invitrogen cat. # 31985) containing rDIs-T7pol at MOI 0.5-2.0 TCID50. Incubated 
1 hour at 37°C with mild agitation at 15 minute intervals. 
2.3.2 – cDNA Transfection 
53.25µL TransIT-LT1 (Mirus cat. #MIR 230x) added into 0.75mL Opti-MEM I. Vortex 1 
second to mix. Incubated 15 minute at RT. Added plasmid DNA mixture (Table 2). Mix by 
gentle pipetting. Incubated 20 minutes at RT. Removed viral adsorption. Washed infected L cells 
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with growth medium. Added 5mL complete medium to culture dish. Added TransIT-LT1/DNA 
complex mixture to culture dish. Incubated transfected L cells 5 days at 37°C. 
2.4 – Viral Plaque Assay 
Added 1.2 x 106 cells per well in 2 ml cMEM to Costar 6-well plates. Dispersed cells evenly 
within well. Incubated overnight at 37°C to form monolayer. Diluted recombinant virus stock 
into 10 fold delusions using PBS (pH 7.5) + 2 mM MgCl2. Removed existing media from well. 
Added 0.1mL sample and distributed evenly through well. Incubated at RT for 1 hour with 
gentle agitation every 15 minutes. Added 2mL prepared serum-free 2x199 with 1% agar and 10 
mg/ml trypsin to each well and distributed evenly. Allowed incubate at 37°C until solidified. 
Two days post inoculation, proceeded with staining. Added 2mL neutral red per 100mL 2x199 
mixture. Added 2mL to well, allow incubate 37°C. 
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Figure: 5 – DNA Construct Map. Map showing complete construct of S3 from T3D strain Orthoreovirus. Primers and 
duplication method indicated.  
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Name Sequence (5’ 3’) 
(L1) TGA TGA GCA CTT TTA AAG TTC T 
(L2) CCT TAG CAT AGC TAA GCA C 
(R1) TTG GAA AAC GTT CTT CGG GGC G 
(R2) GAG GGC AGG GGC AGC CTG CTG ACC TGC GGC GAC GTG GAG GAG AAC CCC GGC CCC 
(C1) CCC GTG CAG CAG ATC GGC GGC AA 
(C2) AGC AGG CTG CCC CTG CCC TCG TCG TAG GGT GTA CAG CCC 
Table: 1 - Primer Sequence. Table displaying the sequence of primers used in the plasmid construction to express p24 
protein for use in HIV vaccine. 
 
Plasmid Amount (mg) 
pT7-L1 2.0 
pT7-L2 2.0 
pT7-L3 2.0 
pT7-M1 1.75 
pT7-M2 1.75 
pT7-M3 1.75 
pT7-S1 2.0 
pT7-S2 1.5 
pT7-S3 1.5 
pT7-S4 1.5 
Table 1: - DNA Content. Table showing  
concentrations of DNA added to the viral  
stock for creation of recombinant  
Orthoreovirus. 
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3 – Results 
3.1 – Construct Design 
The recombinant virus, after the alterations necessary for the vaccine protein production, must 
still properly infect and propagate. Altering the ORF in any way would cause the proteins 
encoded for by that frame to become altered, possibly losing native functionality. Therefore, a 
method must be devised in which the ORF remains untouched and code is added into the genome 
in such a manor as to produce both the vaccine protein and the native coding proteins. 
The problem arises as to the location of the inserted code. The initial coding region of the 
segment reading frame contain vital sequences to the initiation and regulation of transcription, 
including a 5’ region unique to the particular segmented genome. Placement prior to this location 
would alter this initial 5’ region, resulting in a lack of transcription of the code, thereby leading 
to a lack of production of the protein. Similarly, the end of the reading frame contains coding 
sequence resulting in the termination and finalization of transcription. Placement of code after 
this point would likewise result in a lack of transcription of the protein.  
The most viable solution to this issue is the replication of the reading frame. By replicating the 
reading frame, either in its entirety or in portion, a copy is created, containing all necessary 
transcriptional features, whereby alterations can be made leading to the successful transcription 
of code. Because only the initial sequence of the reading frame is necessary for protein 
production, with the central and terminal regions containing protein code and termination 
sequences, duplication is only necessary of the initial sequence. Depending on the amount of 
duplication, varying forms of fusion proteins can be created. 
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Placement of the duplicated reading frame adjacent to the native must be accompanied with a 
method by which the two regions are separated. Failure to do so could create, depending on the 
transcriptional factors present in the  
The 2A motif is a 54bp oligopeptide sequence that, when present within an ORF, causes a lack 
of the glycyl-prolyl peptide bond at the C-terminus of the sequence31. This allows for the 
separation of proteins, by way of a lack of bond, without the need for the numerous regulatory 
factors or physical separation of code. Because of the compact form for the motif, critical in 
keeping the length of added sequence to a minimum, it was chosen as the method for protein 
separation. The choice of such a motif greatly reduces the number of regulatory and transcription 
factors necessary for the code, and eliminates the need for physical separations of the code itself. 
Due to the manor in which the 2A motif operates, creating a lack in linkage between the motif 
and following sequence at the 3’ end, the protein at the 5’ end will, as a result, contain the 2A 
motif itself. Because the protein encoded for by the native reading frame is necessary to the 
replication of the virion, any changes to the sequence could result in a change to the protein 
function, by way of a structural change. Because of this, the 3’ end of the motif must be affixed 
to the native reading frame, as to insure no superfluous code is transferred to the final resulting 
protein. This then forces the 5’ end to be affixed to the added sequence, forcing duplication and 
insertion to take place prior to the reading frame, at the 5’ end. The resulting construct design is 
pictured (Fig. 4).   
3.2 – S3 Plasmid Fabrication 
In order to construct the plasmid, a series of PCR’s were performed to selectively amplify 
various regions (Fig.5). Two initial PCR’s were performed in order to create the duplication 
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necessary. Primers for PCR [L] were designed in such as manor as to amplify the 200bp 
duplication necessary for addition of the p24 sequence, in combination with the later half of the 
original segment. PCR [R] primer (R1) contained the 2A motif in its entity with overlap of the 5’ 
end, thereby adding the sequence to the 5’ end of the native reading frame, while amplifying the 
initial half of the segment. Following the PCR, an agarose gel was run to insure proper 
amplification as determined by size (Fig. 6). The gel showed an approximate size of 2600bp for 
PCR [R] and 2000bp for PCR [L], corresponding to the expected values of 2605bp and 1984bp 
respectively. A third PCR (PCR [C]) was performed for the amplification of the p24 sequence 
into the PCR[R] product. Following PCR, all products were ligated and a gel run to insure proper 
ligation as determined by size (Fig. 7). Gel indicated product of approximately 4700bp, 
corresponding to expected size of 4739bp. This is a good indication that the PCR’s performed as 
expected. 
3.3 – Plasmid Selection and Amplification 
Following successful ligation, product was transformed into competent bacterial cells for 
amplification. Plated cells were selected for successful transformation via antibiotic screen and 
grown via 3mL culture. Plasmids from cultured cells were harvested and sequenced.  
Sequencing results yielded 51 unaligned bases prior to the start of the known sequence, as well 
as numerous frameshifts and basechanges after the 1000bp mark. Both issues are known results 
of sequencing method, and are in no way indicative of error. The sequence was otherwise clean 
and in line with expected results, indicating plasmid is as designed (Fig. 8).  
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3.4 – Viral Plaque 
Following the confirmation of a correct sequence, a recombinant virus was constructed using the 
method outlined by Takeshi Kobayashi (§ 2.3). The stock created was used to perform a viral 
plaque assay. 
The viral plaque assay was performed under varying dilutions to yield a single selectable viral 
line (Fig. 9). A single plaque selected for sequencing. Sequencing yielded a wild type plasmid, as 
originates from T3D strain (Fig. 10). All modifications to sequence had been eliminated, yielding 
only the T3D reading frame. No evidence of T3D duplication, p24 sequence, of 2A motif were 
present. No recombinant plaques were discovered through repeated assays and sequencing. 
 
Figure: 4 – Construct Design. A representation of the construct design. Initial 200bp of T3D strain reading frame 
replicated, adjacent to region of p24 protein to be expressed. Autocleavage from native reading frame by way of 2A motif. 
Sequence only partial, OOR and remaining segment not shown. 
100 200 300 400 500 600 700 800
T3D ORFT3D-Dup SIV-p24 2A
S3_5'_dupl_2A_fr1
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Figure: 8 - S3 Plasmid Sequencing. Sequencing results following the amplification of the construct as performed by 
competent bacterial cells. Showing correct sequence of 5’ duplication, p24 capsid protein, 2A autocleavage motif, and 
native ORF. No erroneous or unexpected mutations in the first 1000bp as expected.  
Figure: 6 -  PCR [R] [L] Agarose Gel. Gel showing 
correct amplification of PCR [R] and [L]. Arrows 
indicate size on DNA marker used. Approximate 
size of band in PCR[R] determined to be 2600bp 
and 2000bp in PCR[L], corresponding to expected 
values of 2605bp and 1984bp respectively. 
Figure: 7 -  PCR [RC+L] Agarose Gel. Gel showing 
correct ligation of all parts to form plasmid. Arrows 
and associated size indicate size of band on DNA 
marker used. Approximate size of plasmid 
determined to be 4700bp, corresponding to expected 
value of 4739bp. 
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Figure: 9 – Viral Plaque Assay. Growth and selection of recombinant virions in varying dilutions for sequencing. Wells 
plated in 10-fold dilution (increasing dilution right   left) series and allowed grow >1 month for the expression of 
plaques used to sequence obtained Orthoreovirus S3 segment. 
 
 
Figure: 10 – Viral Plaque Sequencing Results. Results from sequencing following viral plaque assaying showing reversion 
back to wild type S3 segment. 5’ duplicated region, p24 capsid protein, and 2A motif all unaccounted for. 
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4 – Discussion 
The deadly and, at this time, incurable nature, of HIV requires the development of a course of 
treatment against the virus. While a cure would be an optimal solution for those already infected, 
a vaccine would best for the prevention of the spread of the virus, which will eventually lead to 
the eradication of the virus from the population. The goal of the 5’ duplication method of 
Orthoreovirus is to create a vaccine by which the p24 HIV capsid protein is expressed, allowing 
immunity from HIV to be granted to the individual. 
4.1 – S3 Segment Recombination 
The plaque assay results were of particular interest. Virion levels obtained from all assay 
concentrations were extremely low in nature. In most cases, multiple infections were necessary 
to obtain a level of virions necessary for sequencing. Since recombination somehow took place 
during infection or replication, this low production of virions may be the result of the 
recombination pathway taking place. The extended time observed could also have been the result 
of selectivity of the pathway, with only a small percentage of recombinant S3 segments being 
taken up, which over multiple infections, greatly reduced the percentage of recombinant to wild 
type segments in the stock. 
The exact mechanism whereby the recombinant form of the S3 Orthoreovirus segment reverts 
back into the wild type segment remains unknown. Due to the likeness in sequence of the ORF 
and the duplicated region, it is feasible that a hairpin created during viral replication causing the 
excision of the recombinant code. This is unlikely however, due to the presence of the 
recombinant code after PCR amplification, as well as bacterial transfection. While contamination 
of the plasmid stock with wild type is possible, the rate of selectivity for wild type over 
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recombinant type necessary to produce a clean wild type sequence as a result of the plaque assay 
would indicate otherwise. Should the selectivity of wild type have taken place, a trace amount of 
recombinant type would still remain present due to the overwhelming amount present, causing 
the sequencing to produce several errors.  
The cause of recombination is most likely due to an unknown pathway within the virion. 
Recognition of duplication, length of the remaining unmodified segments, or foreign code could 
have imparted the virion with the ability to select for the recombinant code and remove it to 
produce the wild type sequence. Preliminary results from further testing indicate possible success 
with a truncated version of SIV-p24 code inserted (data not shown). Success with a shortened 
sequence would indicate the possibility of success with this method, assuming further 
investigation into the method of recombination. This apparent restriction in size is an important 
consideration that must be taken into account with future use and design involving Orthoreovirus 
S3 segment. 
4.2 – S3 5’ Duplication 
Despite the issues encountered, the 5’ duplication of the S3 segment remains the best possible 
approach for the creation of an HIV vaccine by use of Orthoreovirus. The use of a 3’ duplication, 
should a suitable mechanism for separation even be found, would lead to insufficient production 
of the recombinant protein, as a result of incomplete translation due to the finished production of 
the necessary native protein. Insertion mid-coding frame is also not a feasible option, as this 
would ruin the infectivity of the virus. Therefore, duplication of the 5’ region, conserving the 
regulatory and structural components of the genome necessary for translation, is the best choice. 
It is because of this, and the benefits of using Orthoreovirus, including the possibility of inserting 
multiple foreign codes on multiple segments, as well as the similarities of infection in GALT 
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cells between Orthoreovirus and HIV, make it currently one of the best possibilities in the fight 
against HIV. Continued research with this virus may not only lead to results for HIV vaccine, but 
many other pathogens as well, using a similar method of approach. 
4.3 – Continued Research 
Due to the compact size and native coding sequence, the S3 segment remains one of the best 
possible segments of the Orthoreovirus genome for use in recombinant vaccines. Investigations 
into the maximum possible length of foreign code that can be added to this segment would be 
imperative to determine for its use as a vaccine vector. Determination of this would also most 
likely be of assistance in studies on subsequent segments. The method by which recombination 
to wild type takes place is also of great interest, not only in the study of vaccine, but as a study of 
the native function and pathways of the virus. The possibility exists that recombination takes 
place by an otherwise unknown pathway, present not only in Orthoreovirus, which may aid in 
the understanding and development of cures for other pathogens.  
While the S3 segment is, in theory, an excellent choice for a vector, other possibilities exist. The 
L segments, M segments, and remaining S segments are all candidates for the insertion of code, 
and may prove to lack the problems which has thus far been a factor in the use of S3. 
Investigation into the feasibility of these segments is an important consideration, not only for the 
design of an HIV vaccine, but possibly for use in a vaccine that may require a much larger 
coding region inserted. The degree to which these segments can be altered may vary greatly from 
S3, possibly allowing a much larger region of code to be inserted, or for a more stable construct 
to be created.  
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Various other separation motifs may also be investigated. 2A was used due to its compact size 
and clean separation. However, should other motifs or fusion protein separation techniques be 
found to be equally effective, their use into the effect on recombinant code expression in 
Orthoreovirus should also be investigated. Should work with Orthoreovirus provide no 
possibility of results, other viruses should be approached, with the in vivo production of p24 
targeting GALT CD4+ cells as the goal. This method is most likely to provide the strongest 
immunity and best possible results in the fight against HIV infection. 
4.4 – Implications of HIV Vaccine 
In many third world and developing countries, such as those found in Africa, the cure of all HIV 
infected individuals, should a cure be found, would prove to be a highly resource and financially 
difficult task. Such an undertaking would involve the testing, and subsequent treatment, perhaps 
with multiple courses of medication over a span of time, the logistics of which alone would 
prove to be nearly impossible. If eradication of HIV is to be achieved, the prevention of infection 
is a much more realistic goal. By granting immunity to those not already infected, the virus is 
unable to spread to a larger portion of the population, and will eventually be removed from that 
population. Immunity to the virus would also reduce the risk greatly to those in high risk for  
4.5 – Final Considerations 
HIV is perhaps one of the most deadly and feared diseases of our time. With no known cure and 
almost certain unfavorable outcome, the need for a treatment is massive. Despite the issue of 
recombination encountered, the 5’ duplication method remains a feasible contender for this 
treatment. All research and design indicates that success with this method should be obtainable. 
Should the S3 segment prove to be too problematic for use, not only should the method of 
recombination be investigated, but other possibilities within the Orthoreovirus genome, and other 
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viruses, be investigated as well. While the mass production and distribution of a successful HIV 
medication is almost certainly years away, the technology and tools provided here, as well as in 
many other avenues, are available now, and should be taken advantage of to the fullest. 
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